Lexicon Pharmaceuticals reported a net loss of $15.5 million for the fourth quarter of 2025, or $0.04 per share, a sharp improvement from the $33.8 million loss ($0.09 per share) recorded a year earlier. Revenue rose to $5.5 million, beating the consensus estimate of $3.92 million and driven by $4.3 million in licensing revenue from its Novo Nordisk partnership and $1.1 million in net sales of its approved product INPEFA. The earnings beat was driven by disciplined cost control and a favorable mix shift toward high‑margin licensing income.
For the full year, Lexicon generated $45 million in licensing revenue from Novo Nordisk, an upfront payment received in April 2025, up from zero in 2024. Full‑year INPEFA sales fell to $4.6 million from $6.0 million in 2024, a 23.3% decline, reflecting the company’s decision to scale back commercial efforts for the product. Cash and cash equivalents stood at $125.2 million as of December 31 2025, down from $238.0 million in 2024 but bolstered by a $96.7 million equity raise and a $10 million milestone payment from Novo Nordisk in February 2026.
Research and development expenses for the quarter were $11.3 million, while selling, general and administrative costs were $8.8 million. The reductions in both categories were largely attributed to a strategic shift toward an R&D‑focused model and a significant reduction in marketing and promotional spend for INPEFA, which helped the company maintain operating leverage despite a lower product‑sales mix.
Clinical highlights included the continued progress of sotagliflozin, which remains on schedule for a type‑1 diabetes NDA resubmission in 2026. The SONATA Phase 3 trial for hypertrophic cardiomyopathy has completed more than 50% of enrollment and is expected to finish enrollment by mid‑2026. In diabetic peripheral neuropathic pain, the Phase 2b program for pilavapadin achieved a 2‑point average daily pain score reduction at the 10 mg dose, positioning the company for a Phase 3 partnership discussion.
CFO Scott Coiante said the company “strengthened its financial position with more than $100 million in additional cash from a recent capital raise and a milestone payment from Novo Nordisk, which together with rigorous expense discipline provides the financial footing needed to support our pipeline programs.” CEO Mike Exton added that the company “continues to have confidence in the favorable benefit‑risk profile of sotagliflozin for adults with type 1 diabetes and CKD, and the strong results from the PROGRESS Phase 2b study give us great confidence in Phase 3 development of the 10 mg dose for DPNP.”
Following the announcement, Lexicon’s shares fell 4.29% in pre‑market trading. The decline was attributed to profit‑taking after a 385% gain over the past year, valuation concerns relative to the company’s fair‑value estimate, and investor focus on the company’s ongoing cash burn despite the earnings beat.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.